Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research B cell 

    • Diffuse large B-cell lymphoma (DLBCL) 

    • Diagnosis and prognosis 

    • Prognostic indicators 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
      • Glycoengineering
      • Fundamental concepts in B-cell malignancies
      • Chronic lymphocytic leukemia (CLL)
      • Follicular non-Hodgkin's lymphoma (fNHL)
      • Diffuse large B-cell lymphoma (DLBCL)
        • Diagnosis and prognosis
          • Diagnosing DLBCL
          • Staging DLBCL
          • Prognostic indicators
            • Clinical
            • Molecular
        • Treatment strategies
        • Emerging therapeutic options
        • Current issues in DLBCL
        • References
      • Slide decks, videos and downloads
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • CLL
    • DLBCL
    • Follicular Lymphoma
  • Biological Pathways
    • Apoptosis
    • B-cell Surface Proteins
  • Clinical Trials
    • DLBCL
  • Cancer Biomarkers
    • DLBCL
      • CD22
  • Future Directions
    • Non-Antibody Biologics
      • Apoptosis
    • Targeted Small Molecules
      • Apoptosis
    • Traditional Monoclonal Antibodies
      • B-cell Surface Proteins
Share

Prognostic indicators

  • Despite advancements in the treatment of DLBCL, approximately half of patients relapse after treatment or are refractory to treatment3,28
  • A greater understanding of the biology of DLBCL and an assessment of favorable or poor prognosis may facilitate better treatment decisions in the future, ultimately resulting in improved patient outcomes28
  • Investigative efforts to define patient subsets associated with favorable or unfavorable prognoses focus on both clinical and molecular factors28

View References for this site section

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Clinical »

© 2011 Genentech USA, Inc. All rights reserved